eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple endocrine neoplasia type 1 |
| Comorbidity | C1140680|ovarian ca |
| Sentences | 9 |
| PubMedID- 26183052 | The cases were all women in denmark with epithelial ovarian cancer diagnosed during 2000-2009 (paper 1) and 2000-2011 (papers 2 and 3), identified in the cancer registry. |
| PubMedID- 23063762 | The "leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. |
| PubMedID- 20385032 | Computed tomographic (ct) scans of the abdomen in a patient with advanced ovarian cancer and brca mutation family history showed a reduction in the size of a peritoneal tumor nodule by 66% over a 4-month treatment period during which she received a potent parp1 inhibitor, olaparib, at a dose of 100 mg, twice daily, for 2 of every 3 weeks. |
| PubMedID- 21742586 | Treatment was discontinued prior to 6 cycles in 2 of 12 patients secondary to progression in one case and to grade 4 neutropenia and thrombocytopenia in another.the combination of intravenous gemcitabine and an intraperitoneal platinum agent appears to be a feasible regimen in patients with ovarian cancer. |
| PubMedID- 22396450 | ovarian cancer in women is a complex and deadly disease, where the molecular events that initiate and control tumor formation remain poorly defined. |
| PubMedID- 20576343 | The purpose of this study was to provide preliminary toxicity data of carboplatin-based ip chemotherapy and to evaluate the feasibility of this chemotherapy regimen in patients with ovarian cancer after primary debulking surgery. |
| PubMedID- 25834466 | ovarian cancer affected 83% of women in c2007-01. |
| PubMedID- 25599660 | As for the single irinotecan regimen in patients with platinum-resistant ovarian cancer, a phase ii study demonstrated that irinotecan of 300 mg/m2/3 weeks had an orr of 17.2 % and a median pfs of 2.8 months [30]. |
| PubMedID- 21792011 | Possible use of ca-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. |
Page: 1